Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Hypertriglyceridemia: HELP
Articles from Kansas
Based on 8 articles published since 2010

These are the 8 published articles about Hypertriglyceridemia that originated from Kansas during 2010-2020.
+ Citations + Abstracts
1 Review Summation of blood glucose and TAG to characterise the 'metabolic load index'. 2016

Emerson, Sam R / Haub, Mark D / Teeman, Colby S / Kurti, Stephanie P / Rosenkranz, Sara K. ·1Department of Food, Nutrition, Dietetics and Health,Kansas State University,212 Justin Hall, 1324 Lovers Lane, Manhattan,KS 66506,USA. · 2Department of Kinesiology,Kansas State University,1A Natatorium, Manhattan,KS 66506,USA. ·Br J Nutr · Pubmed #27774915.

ABSTRACT: Research points to postprandial glucose and TAG measures as preferable assessments of cardiovascular risk as compared with fasting values. Although elevated postprandial glycaemic and lipaemic responses are thought to substantially increase chronic disease risk, postprandial glycaemia and lipaemia have historically only been considered separately. However, carbohydrates and fats can generally 'compete' for clearance from the stomach, small intestine, bloodstream and within the peripheral cell. Further, there are previous data demonstrating that the addition of carbohydrate to a high-fat meal blunts the postprandial lipaemic response, and the addition of fat to a high-carbohydrate meal blunts the postprandial glycaemic response. Thus, postprandial glycaemia and lipaemia are interrelated. The purpose of this brief review is 2-fold: first, to review the current evidence implicating postprandial glycaemia and lipaemia in chronic disease risk, and, second, to examine the possible utility of a single postprandial glycaemic and lipaemic summative value, which will be referred to as the metabolic load index. The potential benefits of the metabolic load index extend to the clinician, patient and researcher.

2 Review The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia. 2016

Backes, James / Anzalone, Deborah / Hilleman, Daniel / Catini, Julia. ·Atherosclerosis and LDL-Apheresis Center, School of Pharmacy, University of Kansas, 3901 Rainbow Boulevard, Kansas City, KS, 66160, USA. jbackes@kumc.edu. · AstraZeneca, Wilmington, DE, USA. · Creighton University, Omaha, NE, USA. ·Lipids Health Dis · Pubmed #27444154.

ABSTRACT: Hypertriglyceridemia (triglycerides > 150 mg/dL) affects ~25 % of the United States (US) population and is associated with increased cardiovascular risk. Severe hypertriglyceridemia (≥ 500 mg/dL) is also a risk factor for pancreatitis. Three omega-3 fatty acid (OM3FA) prescription formulations are approved in the US for the treatment of adults with severe hypertriglyceridemia: (1) OM3FA ethyl esters (OM3EE), a mixture of OM3FA ethyl esters, primarily eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (Lovaza®, Omtryg™, and generics); (2) icosapent ethyl (IPE), EPA ethyl esters (Vascepa®); and (3) omega-3 carboxylic acids (OM3CA), a mixture of OM3FAs in free fatty acid form, primarily EPA, DHA, and docosapentaenoic acid (Epanova®). At approved doses, all formulations substantially reduce triglyceride and very-low-density lipoprotein levels. DHA-containing formulations may also increase low-density lipoprotein cholesterol. However, this is not accompanied by increased non-high-density lipoprotein cholesterol, which is thought to provide a better indication of cardiovascular risk in this patient population. Proposed mechanisms of action of OM3FAs include inhibition of diacylglycerol acyltransferase, increased plasma lipoprotein lipase activity, decreased hepatic lipogenesis, and increased hepatic β-oxidation. OM3CA bioavailability (area under the plasma concentration-time curve from zero to the last measurable concentration) is up to 4-fold greater than that of OM3FA ethyl esters, and unlike ethyl esters, the absorption of OM3CA is not dependent on pancreatic lipase hydrolysis. All three formulations are well tolerated (the most common adverse events are gastrointestinal) and demonstrate a lack of drug-drug interactions with other lipid-lowering drugs, such as statins and fibrates. OM3FAs appear to be an effective treatment option for patients with severe hypertriglyceridemia.

3 Review Metabolic Syndrome: Hyperlipidemia. 2015

Bragg, Dee Ann Stults / Walling, Anne. ·Department of Family and Community Medicine at the University of Kansas School of Medicine-Wichita, 707 N. Emporia, Wichita, KS 67214. ·FP Essent · Pubmed #26280341.

ABSTRACT: Metabolic syndrome is associated with an elevated risk of cardiovascular disease and premature mortality. When metabolic syndrome includes lipid abnormalities, management goals are weight loss and cardiovascular risk management through lifestyle modifications (eg, diet, exercise), and, when appropriate, lowering of lipid levels with pharmacotherapy. Healthy diets are recommended, particularly the Mediterranean diet. Patients also should set a goal of at least 30 minutes of moderate to vigorous exercise on most, preferably all, days of the week. Guidelines provide criteria for statin treatment based on overall cardiovascular risk. High-intensity statin treatment (eg, rosuvastatin 20 to 40 mg, atorvastatin 40 to 80 mg) typically is recommended unless the patient cannot tolerate therapy. Approximately 5% of patients experience statin-induced myalgia, in which case moderate-intensity treatment can be tried. Lipid levels should be reevaluated 4 to 12 weeks after initiating therapy; lipid levels can be measured without fasting. A lack of improvement often indicates nonadherence. Bile acid sequestrants, fibric acids, and niacin can be used if other drugs are not tolerated. The evidence to support use of integrative medicine is limited, but the strongest evidence of benefit is for garlic (Allium sativum).

4 Article Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles. 2019

O'Dea, Louis St L / MacDougall, James / Alexander, Veronica J / Digenio, Andres / Hubbard, Brant / Arca, Marcello / Moriarty, Patrick M / Kastelein, John J P / Bruckert, Eric / Soran, Handrean / Witztum, Joseph L / Hegele, Robert A / Gaudet, Daniel. ·Akcea Therapeutics, Boston, Massachusetts. · BioBridges, Wellesley, Massachusetts. · Ionis Pharmaceuticals, Carlsbad, California. · Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy. · Department of Medicine, Division of Clinical Pharmacology, University of Kansas Medical Center, Kansas City, Kansas. · Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, AZ Amsterdam, Netherlands. · Institut E3M et IHU Cardiométabolique, Hôpital Pitié-Salpêtrière, Paris, France. · Manchester University Hospital NHS Trust, Manchester, England. · University of California, San Diego, La Jolla, California. · Robarts Research Institute, Western University, London, Ontario, Canada. · Department of Medicine, Université de Montréal and ECOGENE 21, Chicoutimi, Quebec, Canada. ·J Endocr Soc · Pubmed #31777768.

ABSTRACT: Context: Differentiation between familial chylomicronemia syndrome (FCS, type 1 hyperlipoproteinemia), a rare metabolic disorder, and the more common multifactorial severe hypertriglyceridemia (sHTG, type 5 hyperlipoproteinemia) is challenging because of their overlapping symptoms but important in patient management. Objective: To assess whether readily obtainable clinical information beyond triglycerides can effectively diagnose and differentiate patients with FCS from those with sHTG, based on well-curated data from two intervention studies of these conditions. Methods: The analysis included 154 patients from two phase 3 clinical trials of patients with sHTG, one cohort with genetically confirmed FCS (n = 49) and one with multifactorial sHTG (n = 105). Logistic regression analyses were performed to determine the ability of variables (patient demographics, medical history, and baseline lipids, individually or in sets) to differentiate the patient populations. Receiver operating characteristics were used to determine the variable sets with the highest accuracy (percentage of times actual values matched predicted) and optimal sensitivity and specificity. Results: The primary model diagnosed 45 of 49 patients with FCS and 99 of 105 patients with sHTG correctly. Optimal sensitivity for all available parameters (n = 17) was 91.8%, optimal specificity was 94.3%, and accuracy was 93.5%. Fasting low-density lipoprotein cholesterol (LDL-C) provided the highest individual predictability. However, a three-variable set of ultracentrifugally measured LDL-C, body mass index, and pancreatitis history differentiated the diseases with a near similar accuracy of 91.0%, and adding high-density lipoprotein cholesterol and very low-density lipoprotein cholesterol for a five-variable set provided a small incremental increase in accuracy (92.2%). Conclusions: In the absence of genetic testing, hypertriglyceridemic patients with FCS and sHTG can be differentiated with a high degree of accuracy by analyzing readily obtainable clinical information.

5 Article Gender and Age Impact on the Association Between Thyroid-Stimulating Hormone and Serum Lipids. 2015

Meng, Zhaowei / Liu, Ming / Zhang, Qing / Liu, Li / Song, Kun / Tan, Jian / Jia, Qiang / Zhang, Guizhi / Wang, Renfei / He, Yajing / Ren, Xiaojun / Zhu, Mei / He, Qing / Wang, Shen / Li, Xue / Zheng, Wei / Hu, Tianpeng / Liu, Na / Upadhyaya, Arun / Zhou, Pingping / Zhang, Jianping. ·From the Department of Nuclear Medicine (ZM, JT, QJ, GZ, RW, YH, SW, XL, WZ, TH, NL, AU, PZ), Department of Endocrinology and Metabolism (ML, XR, MZ, QH), Department of Health Management, Tianjin Medical University General Hospital (QZ, LL, KS), and Department of Nuclear Medicine, Tianjin Third Central Hospital, Tianjin, P.R. China (JZ). ·Medicine (Baltimore) · Pubmed #26656346.

ABSTRACT: The relationship between thyroid-stimulating hormone (TSH) and hyperlipidemia is still a topic of debate. We aimed to explore the impact of gender and age on the association between serum TSH and lipid profile in a large cohort of Chinese.This cross-sectional study enrolled 13,915 participants (8565 male, 5350 female), who self-reported as healthy without any known previous diseases. Clinical data including anthropometric measurements, thyroid function, and other serum parameters were collected. The associations between TSH and hyperlipidemia of males and females were analyzed separately after dividing TSH and age into subgroups. Odds ratio for hyperlipidemia was calculated by binary logistic regression models.Young males had significantly higher prevalence of hypercholesterolemia, hypertriglyceridemia, and high serum low-density lipoprotein-cholesterol than females, yet after menopause, females had higher prevalence than males. TSH was positively associated with hyperlipidemia independent of thyroid hormones. Males showed more reduced risks of hyperlipidemia in low TSH concentrations, while females demonstrated more enhanced risks of hyperlipidemia in high TSH concentrations. For instance, if TSH was lower than 0.3 μIU/mL, the risks of developing hypercholesterolemia and hypertriglyceridemia in males were only 0.198 (P < 0.01) and 0.425 (P < 0.05) of the reference TSH risks (between 2.0 and 3.0 μIU/mL), while in females the risks were 0.553 (P < 0.05) and 0.642 (P > 0.05), respectively. If TSH was higher than 4.0 μIU/mL, women displayed significantly higher risks of developing hypertriglyceridemia than the reference TSH risks (P < 0.05), yet, men did not demonstrate such significances.Our results showed thyroid hormone independent positive associations between serum TSH and lipids, which were substantially influenced by gender and age. Males demonstrated more protective effects of low TSH against hyperlipidemia, while females showed more detrimental effects of high TSH on hyperlipidemia.

6 Article Hypertriglyceridaemia unresponsive to multiple treatments. 2015

Backes, James M / Dayspring, Thomas D / Hoefner, Daniel M / Moriarty, Patrick M. ·Department of Pharmacy Practice, University of Kansas School of Pharmacy, Kansas City, Kansas, USA. · Foundation for Health Improvement and Technology, Richmond, Virginia, USA. · Health Diagnostics Laboratory Inc, Richmond, Virginia, USA. · Division of Clinical Pharmacology, Department of Medicine, Kansas University Medical Center, Kansas City, Kansas, USA. ·BMJ Case Rep · Pubmed #26468219.

ABSTRACT: A 52-year-old man with a longstanding history of hypertriglyceridaemia (approximately 7 mmol/L (600 mg/dL)), unresponsive to treatment, presented to a lipid-specialty clinic. Additional triglyceride-lowering therapies were added with no effect. It was then noted that despite the apparent hypertriglyceridaemia, his serum sample was clear. A 'glycerol blank' was then requested from an advanced lipid laboratory, which reported a triglyceride value of 0.7 mmol/L (62 mg/dL). These findings suggest isolated asymptomatic glycerol kinase deficiency (GKD) or 'pseudohypertriglyceridaemia'. The falsely elevated triglyceride values in such individuals are a result of excess serum glycerol and clinical laboratories measuring glycerol to report triglyceride concentrations. After discontinuation or modification of the patient's primary triglyceride-lowering agents, the lipid panels and triglyceride values remained comparable to previous readings. Recognition of asymptomatic GKD is important to prevent unnecessary treatment and overestimated cardiovascular risk.

7 Article Pseudohypertriglyceridemia: two cases of probable glycerol kinase deficiency. 2012

Backes, James M / Dayspring, Thomas / Mieras, Thomas / Moriarty, Patrick M. ·Atherosclerosis and LDL-Apheresis Center, Kansas University Medical Center, Room B440 Mail Stop 4047, Kansas City, KS 66160, USA. jbackes@kumc.edu ·J Clin Lipidol · Pubmed #23009783.

ABSTRACT: The National Cholesterol Educational Program Adult Treatment Panel's third report define borderline-high, high, and very high triglycerides as serum levels of 150-199 mg/dL, 200-499 mg/dL, and ≥500 mg/dL, respectively. Hypertriglyceridemia (HTG) is generally very responsive to both therapeutic lifestyle changes (TLC), and drug therapy, with niacin, omega-3 fatty acids, fibrates, and statins, each reducing levels by ~10-50%. This paper presents two cases of patients who were aggressively treated for significant HTG with little response to therapy. Although most measured triglyceride (TG) values in these patients were markedly elevated, periodic concentrations were reported as normal. When this occurs, the clinician must immediately think of the diagnosis 'pseudohypertriglyceridemia' or as it is more aptly termed 'glycerolemia' secondary to glycerol kinase deficiency (GKD).

8 Minor Pseudohypertriglyceridemia--verifying the hypertriglyceridemic patient. 2013

Backes, James M / Dayspring, Thomas / Moriarty, Patrick M. ·Kansas City, KS, USA. ·J Clin Lipidol · Pubmed #23415440.

ABSTRACT: -- No abstract --